Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial

被引：0
|
作者：
Lawrence A. Leiter
Stephen C. Bain
Irene Hramiak
Esteban Jódar
Sten Madsbad
Theis Gondolf
Thomas Hansen
Ingrid Holst
Ildiko Lingvay
机构：
[1] Li Ka Shing Knowledge Institute,Division of Endocrinology and Metabolism
[2] St. Michael’s Hospital,Diabetes Research Unit Cymru
[3] University of Toronto,undefined
[4] Swansea University Medical School,undefined
[5] University of Western Ontario,undefined
[6] Hospital Universitario Quirónsalud,undefined
[7] University of Copenhagen,undefined
[8] Novo Nordisk A/S,undefined
[9] UT Southwestern Medical Center,undefined
来源：
Cardiovascular Diabetology | / 18卷
关键词：
Semaglutide; Cardiovascular events; Gender; Age; Baseline cardiovascular risk; Type 2 diabetes; SUSTAIN 6; Cardiovascular outcome trial;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial
    Leiter, Lawrence A.
    Bain, Stephen C.
    Hramiak, Irene
    Jodar, Esteban
    Madsbad, Sten
    Gondolf, Theis
    Hansen, Thomas
    Holst, Ingrid
    Lingvay, Ildiko
    CARDIOVASCULAR DIABETOLOGY, 2019, 18 (1)
  • [2] Effect of once-weekly semaglutide on insulin use in subjects with type 2 diabetes: a post hoc analysis of SUSTAIN 6
    Seufert, J.
    Desouza, C.
    Kirk, A. R.
    Lawson, J.
    Lingvay, I.
    Sondergaard, A. L.
    Bain, S. C.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 251 - 252
  • [3] Effects of once-weekly semaglutide on major adverse cardiovascular events in patients with type 2 diabetes and polyvascular disease: a post hoc analysis of the SUSTAIN 6 trial
    Kobo, O.
    Cavender, M. A.
    Gylvin, S. Hinsch
    Kuhlman, A. B.
    Rasmussen, S.
    Verma, S.
    EUROPEAN HEART JOURNAL, 2023, 44
  • [4] Once-weekly semaglutide reduces the risk of cardiovascular events in people with type 2 diabetes and polyvascular disease: A post hoc analysis
    Kobo, Ofer
    Cavender, Matthew A.
    Jensen, Thomas Jon
    Kuhlman, Anja Birk
    Rasmussen, Soren
    Verma, Subodh
    DIABETES OBESITY & METABOLISM, 2024, 26 (03): : 1129 - 1132
  • [5] Impact of baseline characteristics on the efficacy of once-weekly subcutaneous semaglutide among participants with type 2 diabetes: A post hoc analysis of SUSTAIN China
    Ji, Linong
    Lu, Yibing
    Shen, Zewei
    Hu, Ping
    Liu, Wenyan
    Zhang, Qiu
    Shi, Bimin
    DIABETES OBESITY & METABOLISM, 2024, 26 (11): : 5312 - 5324
  • [6] Efficacy and safety of once-weekly semaglutide in elderly subjects with type 2 diabetes: post hoc analysis of SUSTAIN 1-5 trials
    Warren, M.
    Chaykin, L.
    Trachtenbarg, D.
    Nayak, G.
    Wijayasinghe, N.
    Cariou, B.
    DIABETOLOGIA, 2017, 60 : S378 - S379
  • [7] Semaglutide consistently reduces cardiovascular risk in patients with type 2 diabetes regardless of baseline cardiovascular risk level: post hoc analyses of the SUSTAIN trial programme
    Bain, S.
    Rea, R.
    Warren, M.
    Holst, A. G.
    Vrazic, H.
    Madsbad, S.
    EUROPEAN HEART JOURNAL, 2018, 39 : 598 - 598
  • [8] Once-weekly semaglutide vs canagliflozin in type 2 diabetes: results of the SUSTAIN 8 trial
    Lingvay, I.
    Catarig, A.
    Frias, J. P.
    Kumar, H.
    Lausvig, N. L.
    le Roux, C. W.
    Thielke, D.
    Viljoen, A.
    McCrimmon, R. J.
    DIABETOLOGIA, 2019, 62 : S27 - S28
  • [9] Effects of Once-Weekly Semaglutide on Kidney Disease Outcomes by KDIGO Risk Category in the SUSTAIN 6 Trial
    Tuttle, Katherine R.
    Bain, Stephen C.
    Bosch-Traberg, Heidrun
    Khunti, Kamlesh
    Rasmussen, Soren
    Sokareva, Ekaterina
    Cherney, David Z.
    KIDNEY INTERNATIONAL REPORTS, 2024, 9 (07): : 2006 - 2015
  • [10] Study Design and Baseline Profile for Patients with Type 2 Diabetes in the Semaglutide Once-Weekly Randomized Pragmatic Trial (SEPRA)
    Willey, Vincent
    Buse, John B.
    Harty, Brian
    Mitchell, Julie L.
    Soule, Benjamin P.
    Christensen, Helene N.
    Cziraky, Mark J.
    Skibsted, Simon
    DIABETES, 2022, 71
12345